M⌬hamed Seleem 👨‍🔬🧪

Life is a long experiment

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@ZSCOfficial

[Zamalek SC @ZSCOfficial]

أبطــــــال الـــــــدوري 🏹🌟

#Zamalek | #MostTitledIn20C | #الزمالك_أولًا | #أكبر_قلعة_رياضية

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@ZSCOfficial ماتش سئ جدا من المدرب واللعيبه مفيش صناعة لعب ولا ماسكين كوره ولا فيه نيه للفوز

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@DrLCsquare Congratulations

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@JazanUniversity ماشاء الله
مبارك معالي الدكتور
بالتوفيق والسداد

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

Expected endpoint and great milestone !

[Ingo Hartung @HartungIngo]

It‘s time to remove the question mark!

A huge congrats to @CraigMCrews, Ray Deshaies and the scientists @ArvinasInc.

1st FDA approval for a #PROTAC on May 1st 2026. A day to remember. Extra drinks at the Proxidrugs GRC in a few weeks!

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@HartungIngo Thanks for your efforts. We enjoyed your coverage of the event

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

Impressive

[Black Hole @konstructivizm]

River Nile as seen from Space.. .
NASA
ISS

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@MAFouad @MMohieldin27 @almentornet بالتوفيق يا دكتور. هل الكورس محتوي أكاديمي للمتخصصين أم يستهدف المهتمين بعلم الإقتصاد عامة؟

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@a5medv ساعتين ف ٣ كم بالظبط

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@hishamezzalarab @essam_fahmi بعضنا لا يُجِيد أدب الحوار

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@jenheemstra @Harvard_Press Great! Availability in other platforms as apple and google would be more convenient

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@MAFouad أكيد فيه إحتياج عاجل للقطع دي يا دكتور. أن تأتي متأخرا خير من أن لا تأتي أبدا

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@nagiblab @ScienceMagazine Congratulations

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

Targeting an “inside oncology” goal for TPD could accelerate the development of a reliable market-ready treatment !

[drug hunter @drughunter_com]

KT-474: The First Clinically Active Heterobifunctional Degrader Outside Oncology has its Development Discontinued | https://t.co/t27knV79Gy

Kymera Therapeutics’ IRAK4 degrader, KT-474, was the first heterobifunctional degrader to show clinical activity in non-oncology indications, including atopic dermatitis and hidradenitis suppurativa, leading to its nomination as a 2023 Molecule of the Year.
Kymera’s partner, Sanofi, had initiated a number of Ph. 2 studies of KT-474 in HS and AD, restoring life to IRAK4 as an immunology target after Pfizer dropped its lead IRAK4 inhibitor, zimlovisertib (PF-06650833).

However on June 25, 2025, Sanofi announced that it plans to halt development of KT-474 and instead advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485.

This updated article highlights the science behind the KT-474 program, including how it differentiates from small molecule inhibitors, its potential competitiveness with biologics and the first reported Cryo-EM ternary complex of a heterobifunctional degrader.

Despite its discontinuation, this 2023 Molecule of the Year Nominee will likely be considered a “landmark in drug discovery” for some time.

Read it on Drug Hunter | https://t.co/t27knV79Gy

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@OrgSynth Cool

[Michael Weintraub, MD @MWeintraubMD]

The oral non-peptide GLP-1 agonist space is quickly filling up

#ADA2025 #ADASciScessions

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@LevinChem @NatureChemistry Super cool!

[M⌬hamed Seleem 👨‍🔬🧪 @MSeleem85]

@MAFouad صحيح. المطارات كنز في دوله سياحية ز��نا.